Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Recent Advances in Anti-Infective Drug Discovery
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 2772-4344
  • E-ISSN: 2772-4352

Abstract

Introduction

Recent research has been concentrated on investigating the involvement of () in the progression of liver disorders. This study aims to investigate the prevalence of infection in patients with non-alcoholic fatty liver disease (NAFLD), as well as the effects of toxoplasmosis infection on biological biomarkers such as aspirate transaminase (AST), alanine transaminase (ALT), cholesterol (Chol), and triglyceride (Tg) levels in Sistan, southeast Iran.

Methods

A case-control study was conducted between December 2021 and September 2022. The study included 225 patients diagnosed with NAFLD as the case group and 225 healthy blood donors as the control group. The controls were selected from the same region and were matched with the patients based on gender and age. We collected serum samples from all patients and utilized an enzyme-linked immunosorbent assay to analyze them for the existence of anti- IgG antibodies. A questionnaire and medical records were utilized to gather data on the patient's demographic factors.

Results

The prevalence of anti- IgG antibodies were 68 (30.2%) in patients with NAFLD, whereas it was 11 (4.88%) in the control group. The seroprevalence of in NAFLD patients increased in correlation with age ( < 0.001). The prevalence of NAFLD was significantly greater in the seropositive group compared to the seronegative group ( < 0.001). In addition, the levels of the metabolic markers Chol and Tg were significantly higher in seropositive NAFLD patients compared to seronegative NAFLD patients.

Conclusion

The findings of this study indicate a high seroprevalence of in patients with NAFLD. Further studies are warranted to investigate the underlying mechanisms and potential therapeutic implications of this association.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raaidd/10.2174/0127724344286367240221082018
2024-03-04
2025-05-22

  • From This Site

    /content/journals/raaidd/10.2174/0127724344286367240221082018
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FoeI.T. ChildM.A. MajmudarJ.D. Global analysis of palmitoylated proteins in Toxoplasma gondii.Cell Host Microbe201518450151110.1016/j.chom.2015.09.006 26468752
     [Google Scholar]
  2. LouridoS. Toxoplasma gondii.Trends Parasitol.2019351194494510.1016/j.pt.2019.07.001
     [Google Scholar]
  3. AlmeriaS. DubeyJ.P. Foodborne transmission of Toxoplasma gondii infection in the last decade. An overview.Res. Vet. Sci.202113537138510.1016/j.rvsc.2020.10.019 33148402
     [Google Scholar]
  4. Galván-RamírezM.L. Sánchez-OrozcoL.V. Gutiérrez-MaldonadoA.F. PérezL.R. Does Toxoplasma gondii infection impact liver transplantation outcomes? A systematic review.J. Med. Microbiol.201867449950610.1099/jmm.0.000694 29458555
     [Google Scholar]
  5. SoltaniS. GhaffariA.D. KahvazM.S. SabaghanM. PashmforoshM. ForoutanM. Detection of anti-toxoplasma gondii IgG and IgM antibodies and associated risk factors during pregnancy in Southwest Iran.Infect. Dis. Obstet. Gynecol.202120211610.1155/2021/5547667 34135564
     [Google Scholar]
  6. ShojaeeS. RahbariA.H. KeshavarzH. The relations between anti-toxoplasma IgG and IgM antibodies with avidity index.Crescent J. Med. Biol. Sci.201744177179
     [Google Scholar]
  7. BabekirA. MostafaS. Obeng-GyasiE. The association of toxoplasma gondii IgG and cardiovascular biomarkers.Int. J. Environ. Res. Public Health2021189490810.3390/ijerph18094908 34062965
     [Google Scholar]
  8. BabekirA. MostafaS. Obeng-GyasiE. The association of toxoplasma gondii IgG antibody and chronic kidney disease biomarkers.Microorganisms202210111510.3390/microorganisms10010115 35056564
     [Google Scholar]
  9. El-HenawyA. Abdel-RazikA. ZakariaS. ElhammadyD. SaudyN. AzabM.S. Is toxoplasmosis a potential risk factor for liver cirrhosis?Asian Pac. J. Trop. Med.201581078479110.1016/j.apjtm.2015.09.003 26522292
     [Google Scholar]
  10. KalogeropoulosD. SakkasH. MohammedB. Ocular toxoplasmosis: A review of the current diagnostic and therapeutic approaches.Int. Ophthalmol.202242129532110.1007/s10792‑021‑01994‑9 34370174
     [Google Scholar]
  11. ShihR.Y. KoellerK.K. Central nervous system lesions in immunocompromised patients.Radiol. Clin. North Am.20195761217123110.1016/j.rcl.2019.07.002 31582046
     [Google Scholar]
  12. HuangJ. ZhangH. LiuS. Is Toxoplasma gondii infection correlated with nonalcoholic fatty liver disease?- A population-based study.BMC Infect. Dis.201818162910.1186/s12879‑018‑3547‑1
     [Google Scholar]
  13. ChalasaniN. YounossiZ. LavineJ.E. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.Hepatology201867132835710.1002/hep.29367 28714183
     [Google Scholar]
  14. HeJ.J. MaJ. ElsheikhaH.M. SongH.Q. HuangS.Y. ZhuX.Q. Transcriptomic analysis of mouse liver reveals a potential hepato-enteric pathogenic mechanism in acute Toxoplasma gondii infection.Parasit. Vectors20169142710.1186/s13071‑016‑1716‑x 27488578
     [Google Scholar]
  15. DalimiA. HamidipourL. GhaffarifarF. Toxoplasmosis in patients with chronic hepatitis C and patients with fatty liver.Pathobiol Res20202341723
     [Google Scholar]
  16. Alvarado-EsquivelC. Torres-BerumenJ.L. Estrada-MartínezS. LiesenfeldO. Mercado-SuarezM.F. Toxoplasma gondii infection and liver disease: A case-control study in a Northern Mexican population.Parasit. Vectors2011417510.1186/1756‑3305‑4‑75 21569516
     [Google Scholar]
  17. El-SayedN. RamadanM. RamadanM. Toxoplasma gondii infection and chronic liver diseases: Evidence of an association.Trop. Med. Infect. Dis.201611710.3390/tropicalmed1010007 30270858
     [Google Scholar]
  18. JonesJ.L. PriceC. WilkinsP.P. Kruszon-MoranD. RiveraH.N. Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades.Am. J. Trop. Med. Hyg.20149061135113910.4269/ajtmh.14‑0013 24710615
     [Google Scholar]
  19. JonesJ.L. Kruszon-MoranD. ElderS. Toxoplasma gondii infection in the United States, 2011-2014.Am. J. Trop. Med. Hyg.201898255155710.4269/ajtmh.17‑0677 29260660
     [Google Scholar]
/content/journals/raaidd/10.2174/0127724344286367240221082018
Loading
Seroepidemiology of Toxoplasma gondii Infection in Patients with Liver Disease in Southeastern Iran
Recent Adv Antiinfect Drug Discov 20, 30 (2025); https://doi.org/10.2174/0127724344286367240221082018
/content/journals/raaidd/10.2174/0127724344286367240221082018
/content/journals/raaidd/10.2174/0127724344286367240221082018
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): IgG antibodies; Liver disease; non-alcoholic fatty liver; seroepidemiology; seroprevalence; Toxoplasma gondii

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test